Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR TKI and Early SBRT for Advanced EGFR-Mutant NSCLC
NCT03727867Phase 3Unknown
- Start
- Jun 2019
- Primary completion
- Jun 2021
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03727867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03727867.